Navigation Links
Very early treatment may be key to combatting inherited metabolic disorder
Date:8/4/2014

A European Journal of Neuroscience study suggests that it is critical to treat lysosomal storage disorders early, before symptoms arise. These genetic disorders, which are caused by the malfunction of enzymes that normally degrade various substances within cells, lead to numerous ailments including neurological problems.

Although few therapeutic options are available, clinical trials of treatments including lysosomal enzyme replacement are underway. Researchers who used enzyme replacement to treat mice with early, mid- and later-stages of a lysosomal storage disease found that treatment was most effecting in mice with very early-stage disease. Once symptoms arose, treatment was ineffective.

"Until newborn screening is available world-wide for these conditions, and children are diagnosed prior to symptoms appearing, it is critical that we continue to gather information regarding the reversibility, or not, of disease-based degenerative changes," said senior author Dr. Kim Hemsley.


'/>"/>
Contact: Nicole Weingartner
sciencenewsroom@wiley.com
201-748-5808
Wiley
Source:Eurekalert  

Page: 1

Related medicine news :

1. Theres No Ebola Cure, But Early Intensive Treatment Boosts Survival
2. Early Stem Cell Transplant Vital in Bubble Boy Disease
3. Soy may help womens hearts if they start early
4. Early Hormone Therapy May Be Safe for Womens Hearts
5. Back2Basics Sober Living Resident Overcomes Obstacle in Early Sobriety
6. Study helps compare risks of treatments for early esophageal cancer
7. Wearable device for the early detection of common diabetes-related neurological condition
8. Rx Drug Abuse Labeled Silent Killer: Claims Nearly 17,000 American Lives a Year; Novus Medical Detox Solution Involves Education and Governmental Support
9. Kidney transplant drug halves the early risk of rejection and allows less toxic treatment
10. Early warning sign for babies at risk of autism
11. Parents Death May Raise Risk of Early Death for Grown Children, Study Suggests
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Very early treatment may be key to combatting inherited metabolic disorder
(Date:4/28/2017)... Mateo, CA (PRWEB) , ... April 28, 2017 , ... ... Area cities as diverse as Millbrae, Burlingame, and Palo Alto, is proud to announce ... allow interested persons to bookmark and read organized content on topics such as home ...
(Date:4/27/2017)... (PRWEB) , ... April 27, 2017 , ... ... nation’s leading respiratory hospital, based in Denver, Colorado, announced an agreement to create ... by the continuing support of the Jane and Leonard Korman Family Foundation. The ...
(Date:4/27/2017)... ... April 27, 2017 , ... ... Gasby the 2017 Public Leadership in Neurology Award (PLINA). The couple joins a ... Tedy Bruschi, Vice President Walter Mondale, actor Michael J. Fox and former U.S. ...
(Date:4/27/2017)... Malibu, CA (PRWEB) , ... April 27, 2017 , ... ... United States with an oil many times purer and more potent than the market ... mountain air of Gstaad, Switzerland, as well as a patented chromatography process for extraction, ...
(Date:4/26/2017)... ... April 26, 2017 , ... ... today released the podcast, “Make Plans for MACRA,” highlighting the impact ... the physician's office and how physicians and other clinicians are reimbursed for the ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... April 20, 2017  Zimmer Biomet Holdings, Inc. (NYSE ... today announced that it will be participating in the ... the InterContinental Hotel in Boston, Massachusetts ... present at 11:20 a.m. Eastern Time. A ... Zimmer Biomet,s Investor Relations website at http://investor.zimmerbiomet.com .  ...
(Date:4/20/2017)... DUBLIN , April 20, 2017 Research ... Delivery Technologies - Innovation Driven by Rapidly Expanding Injectables Market and ... to their offering. ... market for drug delivery technologies will rise from USD 20 Billion ... Global Drug Delivery Technologies - Innovation Driven by Rapidly ...
(Date:4/20/2017)...  AbbVie (NYSE: ABBV), a global biopharmaceutical company, ... hepatitis C virus (HCV) infected patients with genotype ... cirrhosis (Child-Pugh A) achieved sustained virologic response at ... investigational, pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). These high ... weeks of G/P treatment without ribavirin. Patients with ...
Breaking Medicine Technology: